An Open Label, Two Stage, Phase II Study to Evaluate the Efficacy and Tolerability of ZD6474 in Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Carcinoma.
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Objective Response Rate
The ORR is the number of patients that are responders ie those patients with a confirmed best objective response of complete response (CR) or partial response (PR) defined according to RECIST 1.0.
Pre-dose and every 12 weeks up to RECIST progression as defined according to RECIST 1.0.
AstraZeneca ZD6474 Medical Science Director, MD
United States: Food and Drug Administration
|Research Site||Anaheim, California|
|Research Site||Danbury, Connecticut|
|Research Site||Branson, Missouri|
|Research Site||Abilene, Texas|